Reviva Pharmaceuticals will present research data on brilaroxazine's treatment effects on negative symptoms in schizophrenia patients at the CNS Summit 2025 in Boston, Massachusetts.

Reviva Pharmaceuticals announced a public offering of 27 million shares and accompanying warrants, raising approximately $9 million to fund research and development activities and working capital.

The schizophrenia market is expected to grow significantly by 2034, driven by rising disease prevalence, expanding approved therapies, and the anticipated launch of new treatments such as Olanzapine LAI, Iclepertin, Ulotaront, and Brilaroxazine.

Reviva Pharmaceuticals Holdings, Inc. (RVPH), a late-stage pharmaceutical company, announced that its Founder, President, and CEO will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, focusing on tackling mental health through new targets and endpoints progress.

The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.